1. Scrip

Poxel/Sumitomo's Novel Diabetes Therapy Imeglimin Nears Japan Market

A Phase III-Ready Partnering Opportunity For EU/US

 
• By John Davis

Poxel’s potential first-in-class diabetes therapy, imeglimin, could be approved in Japan this year, and a new partner is being sought for the EU and US – events that would transform the outlook for the decade-old Merck Serono spin-out.    

mitochondria
Imeglimin Targets Mitochondria Dysfunction • Source: Shutterstock

The metabolic diseases company, Poxel SA, expects its novel antidiabetic, imeglimin, will be approved in Japan this year, through partner Sumitomo Dainippon Pharma Co., Ltd., and also believes the candidate is a Phase III-ready opportunity for a potential partner to develop for the US and EU. 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas